The Protein Corona on Nanoparticles for Tumor Targeting in Prostate Cancer—A Review of the Literature and Experimental Trial Protocol
2024

Nanoparticles and Protein Corona in Prostate Cancer

Sample size: 60 publication 10 minutes Evidence: moderate

Author Information

Author(s): Bevilacqua Giulio, Corvino Roberta, Capriotti Anna Laura, Montone Carmela Maria, Moriconi Martina, Salciccia Stefano, Brunelli Valentina, Santarelli Valerio, Sciarra Beatrice, Laganà Aldo, Santini Daniele, Sciarra Alessandro, Gentilucci Alessandro

Primary Institution: University Sapienza, Rome, Italy

Hypothesis

Identifying disease-specific protein corona nanoparticle systems could complement genetic analysis in the tailoring of therapeutic options for prostate cancer patients.

Conclusion

The study suggests that protein corona nanoparticles can serve as molecular biomarkers to differentiate between benign and malignant prostatic diseases and predict responses to systemic therapy.

Supporting Evidence

  • Protein corona composition can change between patients with and without cancer.
  • Nanoparticles can be used to detect early changes in protein concentration related to cancer.
  • Different studies have shown that the protein corona can influence the behavior of nanoparticles in cancer treatment.

Takeaway

Researchers are studying tiny particles that can help doctors tell the difference between healthy and sick people by looking at the proteins that stick to them.

Methodology

The study involves a prospective single-center trial with patients allocated into three groups based on their prostate condition, using nanoparticles to analyze protein coronas in blood samples.

Potential Biases

Potential biases may arise from sample size and variability in individual patient responses.

Limitations

The complexity of the methodology and technology required for protein corona nanoparticles’ isolation may limit accessibility and widespread application.

Participant Demographics

Male patients aged 40-90 years, including healthy individuals, those with benign prostatic hyperplasia, and patients with prostate cancer.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3390/biology13121024

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication